Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Exploratory Phase IIa Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Patients With Pyoderma Gangrenosum (OPTIMA)

NCT03971643 is registered in ClinicalTrials.gov with InflaRx GmbH as lead sponsor.

NCT NCT03971643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Exploratory Phase IIa Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Patients With Pyoderma Gangrenosum (OPTIMA)
Lead sponsor
InflaRx GmbH
Phase
Phase 2
Overall status
Completed
Start date
May 16, 2019
Completion date
January 3, 2022
Enrollment
19 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

pyoderma gangrenosum